Filling and freeze-drying drivers for $950m Cook deal says Catalent

By Gareth Macdonald contact

- Last updated on GMT

Filling and freeze-drying drivers for $950m Cook deal says Catalent

Related tags: Syringe

Catalent has cited Cook’s ability to make and freeze-dry liquid drugs as major drivers for its planned takeover and said it is keen to take on the firm’s biopharma customers.

The New Jersey, US contractor announced its intention to buy Cook Pharmica on Tuesday​, explaining the $950m (€794m) deal is designed to expand its biopharmaceutical manufacturing and bioanalysis capabilities.

A Catalent spokesman expanded on this, telling us “There are areas where Cook Pharmica brings additional capabilities, for example in handling liquid and lyophilized vials as well as syringes and cartridges, but Cook Pharmica is attractive for many reasons​.”

He cited Cook’s facility in Bloomington, Indiana as key, explaining “its vial and pre-filled syringe lines are fully automated and meet the latest customer and regulatory needs.

“Its biomanufacturing operations are designed to handle a wide range of batch sizes too, similar to what we’ve been able to achieve in Madison, Wisconsin​.”

The spokesman also said customer demand had played a part in driving the acquisition, adding that Cook “has the capabilities and capacity that biologics customers find attractive when choosing a partner​.”

From a capacity standpoint, Bloomington has available expansion space to efficiently support future growth​” he said.

Catalent is also keen to take on contracts with existing Cook customers according to the spokesman.

He said: “Until the acquisition is finalised, we will continue to operate as separate businesses.

Catalent Biologics will work with Cook Pharmica and its customers to maintain existing relationships and ensure minimal customer impact​.”

Related news

Show more

Related products

show more

Shifting the Biomanufacturing Paradigm

Shifting the Biomanufacturing Paradigm

Take the Right Path Upstream with MilliporeSigma | 12-May-2020 | Technical / White Paper

The first commercial monoclonal antibody (mAb) was approved in 1986 and today, the global market is large and growing. Reports estimate the size of the...

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 20-Jan-2020 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Related suppliers

Follow us


View more